Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach

Journal of Paediatrics and Child Health

Volumn 47, Issue 12, 2011, Pages 875-882

  Moore, Andrew S ^a   Norris, Ross ^b,c,d   Price, Gareth ^b   Nguyen, Thu ^b   Ni, Ming ^c   George, Rani ^b   Van Breda, Karin ^b   Duley, John ^b,c   Charles, Bruce ^c   Pinkerton, Ross ^a  

^a Royal Children's and Mater Children's Hospitals   (Australia)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

CYP3A; oncology; pharmacogenetics; pharmacology; population pharmacokinetics; vincristine

Indexed keywords

CORTICOSTEROID; CYTOCHROME P450 3A5; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CHILD; CHILDHOOD CANCER; CONSTIPATION; DNA POLYMORPHISM; DRUG CLEARANCE; GEL ELECTROPHORESIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; PHARMACOGENETICS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMET ASSAY; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; NEOPLASMS; NEUROTOXICITY SYNDROMES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; VINCRISTINE;

EID: 84155168974     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02103.x     Document Type: Article

References (31)

1. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS,. Vincristine revisited. Crit. Rev. Oncol. Hematol. 1999; 29: 267-87. (Pubitemid 29158972)
2. Moore A, Pinkerton R,. Vincristine: can its therapeutic index be enhanced? Pediatr. Blood Cancer 2009; 53: 1180-7.
3. Kauffman RE, Kearns GL,. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin. Pharmacokinet. 1992; 23: 10-29.
4. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR,. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72. (Pubitemid 38499965)
5. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD,. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 2006; 34: 1317-27. (Pubitemid 44079872)
6. Dennison JB, Jones DR, Renbarger JL, Hall SD,. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther. 2007; 321: 553-63. (Pubitemid 46628594)
7. Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD,. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J. Pharmacol. Exp. Ther. 2008; 327: 248-57.
8. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P,. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol. Pharmacol. 1992; 41: 1047-55. (Pubitemid 23026103)
9. Worth LJ, Blyth CC, Booth DL, et al,. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern. Med. J. 2008; 38: 521-37. (Pubitemid 351904423)
10. Kuehl P, Zhang J, Lin Y, et al,. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001; 27: 383-91. (Pubitemid 32268418)
11. van Schaik RH,. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist. Updat. 2008; 11: 77-98.
12. Lonnerholm G, Frost BM, Abrahamsson J, et al,. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br. J. Haematol. 2008; 142: 616-21. (Pubitemid 352020218)
13. Groninger E, Meeuwsen-de Boer T, Koopmans P, et al,. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur. J. Cancer 2005; 41: 98-103. (Pubitemid 40029662)
14. Renbarger JL, McCammack KC, Rouse CE, Hall SD,. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr. Blood Cancer 2008; 50: 769-71. (Pubitemid 351354782)
15. Sheiner LB, Ludden TM,. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 185-209.
16. Ette EI, Williams PJ,. Population pharmacokinetics I: background, concepts, and models. Ann. Pharmacother. 2004; 38: 1702-6. (Pubitemid 39297771)
17. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modeling. Clin. Pharmacokinet. 2008; 47: 231-43. (Pubitemid 351367434)
18. Charles BG,. Fundamentals of population modeling: opportunities for hospital pharmacy practice. Aust. J. Hosp. Pharm. 1999; 29: 88-91.
19. Roy JN, Lajoie J, Zijenah LS, et al,. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 2005; 33: 884-7. (Pubitemid 41002766)
20. NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program 2006.
21. Holford NH,. A size standard for pharmacokinetics. Clin. Pharmacokinet. 1996; 30: 329-32. (Pubitemid 26177179)
22. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimate for diagnostics: problems and solutions. AAPS J. 2009; 11: 558-69.
23. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS,. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother. Pharmacol. 1999; 44: 203-9. (Pubitemid 29350175)
24. Frost BM, Lonnerholm G, Koopmans P, et al,. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2003; 92: 551-7. (Pubitemid 37088699)
25. Kellie SJ, Koopmans P, Earl J, et al,. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 2004; 100: 2637-43. (Pubitemid 38715770)
26. Sethi VS, Jackson DV Jr, White DR, et al,. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 1981; 41: 3551-5. (Pubitemid 11063637)
27. Crom WR, De Graaf SSN, Synold T, et al,. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J. Pediatr. 1994; 125: 642-9. (Pubitemid 24318444)
28. Gupta C, Osterman J, Santen R, Bardin CW,. In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women. J. Clin. Endocrinol. Metab. 1979; 48: 816-20. (Pubitemid 9172119)
29. Chan KK, Gibaldi M,. Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J. Pharmacokinet. Biopharm. 1982; 10: 551-8. (Pubitemid 13185258)
30. Aplenc R, Glatfelter W, Han P, et al,. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 2003; 122: 240-4. (Pubitemid 36859609)
31. U.S. National Institutes of Health. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov [accessed July 2010].